News

As part of the deal, OncoEthix will receive an upfront payment of up to $110m from Merck. Upon certain clinical and regulatory events being achieved, OncoEthix will also

Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, "The submission of an IND for NS2 in the treatment of noninfectious anterior uveitis is a major

The collaborators will use Enumeral’s human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to

OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of BCX4161, 300 mg and 500 mg, administered three-times daily

The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in

The BLA was based on results from the LEOPOLD clinical trials, which evaluated BAY 81-8973 in adults and children using two- and three-times-per-week prophylaxis dosing regimens. BAY 81-8973,

The trial met its primary endpoint showing that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo. HZ/su is

Terms of the transaction were not disclosed. The deal is said to strengthen KCR’s presence in Ukraine, making the country an important location for the firm in the

The drug is approved for patients who are in complete response or partial response to platinum-based chemotherapy. Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits tumor